US3360503A
(en)
*
|
1963-04-09 |
1967-12-26 |
Du Pont |
Process for preparing poly(alpha, alpha-disubstituted beta-lactams)
|
DE2048080C3
(de)
*
|
1970-09-30 |
1979-11-29 |
Basf Ag, 6700 Ludwigshafen |
Verfahren zur Herstellung von N-substituierten 33-disubstituierten ß -Lactamen
|
EP0180398A1
(en)
|
1984-10-26 |
1986-05-07 |
The Regents Of The University Of California |
Synthesis of beta-lactam
|
CA1305177C
(en)
|
1987-06-30 |
1992-07-14 |
Yasufumi Ohfune |
Carboxycyclopropylglycine and process for producing the same
|
US4904681A
(en)
|
1987-12-01 |
1990-02-27 |
G. D. Searle & Co. |
D-cycloserine and its prodrugs as cognitive enhancers
|
EP0360390A1
(en)
|
1988-07-25 |
1990-03-28 |
Glaxo Group Limited |
Spirolactam derivatives
|
US5061721A
(en)
|
1989-03-15 |
1991-10-29 |
G. D. Searle & Co. |
Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
|
US5086072A
(en)
|
1990-06-18 |
1992-02-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
|
WO1992007561A1
(fr)
|
1990-10-30 |
1992-05-14 |
Ss Pharmaceutical Co., Ltd. |
Preparation d'un gel anti-inflammatoire et analgesique
|
US5168103A
(en)
|
1991-01-22 |
1992-12-01 |
American Home Products Corporation |
[[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
|
CA2058223A1
(en)
*
|
1991-12-20 |
1993-06-21 |
Bing-Yan Zhu |
Process for preparing beta-lactams
|
FR2692268B1
(fr)
|
1992-06-15 |
1994-08-19 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides ayant une activité de récepteur NMDA, acides nucléiques codant pour ces polypeptides et utilisations.
|
SE9301667D0
(sv)
|
1993-05-14 |
1993-05-14 |
Kabi Pharmacia Ab |
New use
|
US5523323A
(en)
|
1993-09-14 |
1996-06-04 |
Maccecchini; Maria-Luisa |
Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
|
US5605911A
(en)
|
1995-01-31 |
1997-02-25 |
Washington University |
Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
|
US6335358B1
(en)
|
1995-04-12 |
2002-01-01 |
President And Fellows Of Harvard College |
Lactacystin analogs
|
US5741778A
(en)
|
1996-03-19 |
1998-04-21 |
Amgen Inc. |
Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
|
US5763393A
(en)
|
1996-05-17 |
1998-06-09 |
Neurotherapeutics L.P. |
Neuroactive peptides
|
ATE283278T1
(de)
|
1996-06-07 |
2004-12-15 |
Astrazeneca Ab |
Peptid derivate
|
US5959075A
(en)
|
1996-08-02 |
1999-09-28 |
Zymogenetics, Inc. |
Testis-specific insulin homolog polypeptides
|
US5902815A
(en)
|
1996-09-03 |
1999-05-11 |
Washington University |
Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
|
JP3955345B2
(ja)
|
1996-09-27 |
2007-08-08 |
サントリー株式会社 |
新規アミノ酸ダイジハーベイン
|
WO1999024584A1
(en)
|
1997-11-12 |
1999-05-20 |
Neurotherapeutics |
Methods for the detection and treatment of disease using a glycosyltransferase
|
US5952389A
(en)
|
1998-01-13 |
1999-09-14 |
Synchroneuron |
Methods of treating tardive dyskinesia and other movement disorders
|
US6007841A
(en)
|
1998-03-13 |
1999-12-28 |
Algos Pharmaceutical Corporation |
Analgesic composition and method for treating pain
|
US6274314B1
(en)
|
1998-04-02 |
2001-08-14 |
Nyxis Neurotherapies, Inc. |
Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine
|
US6197820B1
(en)
|
1998-04-06 |
2001-03-06 |
Uab Research Foundation |
Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions
|
US6025471A
(en)
|
1998-06-03 |
2000-02-15 |
Deghenghi; Romano |
Diazaspiro, azepino and azabicyclo therapeutic peptides
|
WO2000027790A1
(en)
|
1998-11-11 |
2000-05-18 |
Smithkline Beecham P.L.C. |
Mutilin compounds
|
WO2000028090A2
(en)
|
1998-11-12 |
2000-05-18 |
Nyxis, Inc. |
Diagnostic assay for cancer
|
US20030064921A1
(en)
|
1999-10-27 |
2003-04-03 |
The Regents Of The University Of California |
Methods and compounds for modulating melanocortin receptor ligand binding and activity
|
WO2001036685A2
(en)
|
1999-11-17 |
2001-05-25 |
Nyxis Neurotherapies, Inc. |
Differential gene expression in cancer
|
JP2003521247A
(ja)
|
2000-02-01 |
2003-07-15 |
エージーワイ セラピューティクス インコーポレーテッド |
Nmda受容体のプロテインチロシンホスファターゼとの相互作用
|
JP2001261679A
(ja)
|
2000-03-21 |
2001-09-26 |
Mitsui Chemicals Inc |
ピロリジノン誘導体及びそれらの製造方法並びに該化合物を含有する医薬
|
WO2001096606A2
(en)
|
2000-06-14 |
2001-12-20 |
Nyxis Neurotherapies, Inc. |
Identification of genes and compounds for treatment of cancer
|
EP1296999A2
(en)
|
2000-06-22 |
2003-04-02 |
NYXIS NeuroTherapies, Inc. |
Neuroactive peptides for treatment of hypoxia and related conditions
|
GB0018272D0
(en)
|
2000-07-25 |
2000-09-13 |
Vernalis Research Limited |
Chemical compounds IV
|
EP1186303A3
(en)
|
2000-09-06 |
2003-12-10 |
Pfizer Products Inc. |
Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
|
IL145209A0
(en)
|
2000-09-06 |
2002-06-30 |
Pfizer Prod Inc |
Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
|
UA73619C2
(en)
|
2000-12-13 |
2005-08-15 |
Pfizer Prod Inc |
Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
|
AU2002236608A1
(en)
|
2000-12-14 |
2002-06-24 |
Nyxis Neurotherapies, Inc. |
High throughput assay to detect inhibitors of the map kinase pathway
|
AU2002248553A1
(en)
|
2001-03-07 |
2002-09-24 |
Cognetix, Inc |
Linear y-carboxyglutamate rich conotoxins
|
AU2002255705A1
(en)
|
2001-03-12 |
2002-09-24 |
Nyxis Neurotherapies, Inc |
Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain
|
US20030022253A1
(en)
|
2001-07-25 |
2003-01-30 |
Nyxis Neurotherapies, Inc. |
Method for identifying, isolating and producing neuroactive binding agents and binding agents derived thereby
|
ES2355157T3
(es)
|
2002-07-05 |
2011-03-23 |
Targacept, Inc. |
Compuestos diazaspirocíclico n-arilo y métodos de preparación y uso de las mismas.
|
US7273889B2
(en)
|
2002-09-25 |
2007-09-25 |
Innovative Drug Delivery Systems, Inc. |
NMDA receptor antagonist formulation with reduced neurotoxicity
|
WO2004094371A2
(en)
|
2003-04-17 |
2004-11-04 |
Merck & Co., Inc. |
Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity
|
EP1776362A1
(en)
|
2003-07-18 |
2007-04-25 |
Virochem Pharma Inc. |
Spiro compounds and methods for the modulation of chemokine receptor activity
|
WO2005014797A2
(en)
|
2003-08-08 |
2005-02-17 |
The Burnham Institute |
P16 mediated regulation of nmda receptors
|
WO2005020973A2
(en)
|
2003-08-29 |
2005-03-10 |
The University Of Houston System |
Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxylamine
|
GB0323204D0
(en)
|
2003-10-03 |
2003-11-05 |
Novartis Ag |
Organic compounds
|
US20050096311A1
(en)
|
2003-10-30 |
2005-05-05 |
Cns Response |
Compositions and methods for treatment of nervous system disorders
|
US20070275990A1
(en)
|
2003-11-13 |
2007-11-29 |
Ono Pharmaceutical Co., Ltd. |
Heterocyclic Spiro Compound
|
ES2359707T3
(es)
|
2004-01-08 |
2011-05-26 |
F. Hoffmann-La Roche Ag |
Derivados de diaza-espiropiperidina.
|
WO2006034196A1
(en)
|
2004-09-17 |
2006-03-30 |
Lifelike Biomatic Inc. |
Compositions for enhancing memory and methods therefor
|
CN101090902B
(zh)
|
2004-10-13 |
2013-05-29 |
默沙东公司 |
Cgrp受体拮抗剂
|
CA2602950C
(en)
|
2005-03-24 |
2012-10-30 |
Emory University |
Methods for the treatment of central nervous system injury via a tapered administration of progesterone
|
CA2620361C
(en)
|
2005-08-26 |
2014-10-14 |
Wisconsin Alumni Research Foundation |
Poly-beta-peptides from functionalized beta-lactam monomers and antibacterial compositions containing same
|
AR059224A1
(es)
|
2006-01-31 |
2008-03-19 |
Jerini Ag |
Compuestos para la inhibicion de integrinas y uso de estas
|
WO2007103719A2
(en)
|
2006-03-03 |
2007-09-13 |
Incyte Corporation |
MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
|
MX2009002921A
(es)
|
2006-09-15 |
2009-04-01 |
Schering Corp |
Derivados de azetidinona para el tratamiento de trastornos del metabolismo lipidico.
|
JP2008188285A
(ja)
|
2007-02-06 |
2008-08-21 |
Bridgestone Corp |
バックパッド及び車両用シート
|
CA2682195A1
(en)
|
2007-03-20 |
2008-09-25 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as kinase inhibitors
|
CN101066945B
(zh)
|
2007-05-25 |
2010-05-19 |
中国科学院上海有机化学研究所 |
一种合成3-位取代内酰胺类化合物的方法
|
CN101125817B
(zh)
|
2007-08-03 |
2011-09-14 |
中国科学院上海有机化学研究所 |
一种合成高对映选择性醛基取代小环胺类化合物和光学活性3-位取代内酰胺类化合物的方法
|
US20090054392A1
(en)
|
2007-08-20 |
2009-02-26 |
Wyeth |
Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
|
WO2009039390A2
(en)
|
2007-09-20 |
2009-03-26 |
Naurex Inc. |
The development of glycobiology-based therapeutics for the treatment of brain tumors
|
EP2257644B1
(en)
|
2008-02-20 |
2015-06-24 |
The Children's Hospital Of Philadelphia |
Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis of autism
|
US20110105480A1
(en)
|
2008-06-24 |
2011-05-05 |
Keith Freehauf |
Pharmaceutical transdermal compositions and method for treating inflammation in cattle
|
RU2011102523A
(ru)
|
2008-06-27 |
2012-08-10 |
Ньюросерч А/С (DK) |
Новые производные тетраметил-замещенного пиперидина и их применение в качестве ингибиторов обратного захвата моноаминовых нейромедиаторов
|
ES2461841T3
(es)
|
2008-08-07 |
2014-05-21 |
F. Hoffmann-La Roche Ag |
Proceso para la preparación de un macrociclo
|
GB0814991D0
(en)
*
|
2008-08-15 |
2008-09-24 |
Glaxo Group Ltd |
Compounds
|
KR101769999B1
(ko)
|
2008-09-18 |
2017-08-21 |
노오쓰웨스턴 유니버시티 |
Nmda 수용체 조절제 및 그의 용도
|
WO2010065709A2
(en)
|
2008-12-03 |
2010-06-10 |
Amin Khan |
Hydroxamic acid derivatives, preparation and therapeutic uses thereof
|
DE102009001460B4
(de)
|
2009-03-11 |
2010-12-02 |
Zf Friedrichshafen Ag |
Ölbehälter
|
US8329904B2
(en)
|
2009-05-12 |
2012-12-11 |
Hoffmann-La Roche Inc. |
Azacyclic derivatives
|
WO2011003064A2
(en)
|
2009-07-02 |
2011-01-06 |
Naurex, Inc. |
Methods of treating neuropathic pain
|
US8951968B2
(en)
|
2009-10-05 |
2015-02-10 |
Northwestern University |
Methods of treating depression and other related diseases
|
RS53513B1
(en)
|
2009-10-05 |
2015-02-27 |
Northwestern University |
GLYX-13 FOR USE IN THE REFRACTOR DEPRESSION TREATMENT PROCEDURE
|
US8871208B2
(en)
|
2009-12-04 |
2014-10-28 |
Abbvie Inc. |
11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof
|
ES2459496T3
(es)
|
2009-12-21 |
2014-05-09 |
Novartis Ag |
Diaza-espiro[5.5]undecanos como antagonistas del receptor de orexina
|
KR101692275B1
(ko)
|
2010-02-11 |
2017-01-04 |
노오쓰웨스턴 유니버시티 |
2차 구조 안정화된 nmda 수용체 조절제 및 그의 용도
|
CN102933226A
(zh)
|
2010-02-11 |
2013-02-13 |
西北大学 |
二级结构稳定化的nmda受体调节剂及其用途
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
US8097634B2
(en)
|
2010-04-15 |
2012-01-17 |
Hoffmann-La Roche Inc. |
Azacyclic derivatives
|
GB201007789D0
(en)
|
2010-05-10 |
2010-06-23 |
Glaxo Group Ltd |
Novel Compound
|
CN102267995A
(zh)
|
2010-06-04 |
2011-12-07 |
艾琪康医药科技(上海)有限公司 |
一种制备二氮杂螺环化合物的方法
|
TW201245116A
(en)
|
2010-08-12 |
2012-11-16 |
Tetraphase Pharmaceuticals Inc |
Tetracycline analogs
|
US9737531B2
(en)
|
2012-07-12 |
2017-08-22 |
Glytech, Llc |
Composition and method for treatment of depression and psychosis in humans
|
KR20140014184A
(ko)
|
2011-02-25 |
2014-02-05 |
아이알엠 엘엘씨 |
Trk 억제제로서의 화합물 및 조성물
|
AP3339A
(en)
|
2011-03-14 |
2015-07-31 |
Boehringer Ingelheim Int |
Benzodioxane inhibitors of leukotriene production
|
KR101309156B1
(ko)
*
|
2011-03-24 |
2013-09-17 |
삼성에스디아이 주식회사 |
리튬 이차 전지용 전해액 및 이를 포함하는 리튬 이차 전지
|
KR20140043078A
(ko)
|
2011-04-27 |
2014-04-08 |
노오쓰웨스턴 유니버시티 |
알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
|
US9293690B2
(en)
|
2011-06-27 |
2016-03-22 |
Koninklijke Philips N.V. |
Ultrasound transducer assembly and method of manufacturing the same
|
CA2842647A1
(en)
|
2011-07-18 |
2013-01-24 |
The Governors Of The University Of Alberta |
Catalysts and processes for the hydrogenation of amides
|
CN104109161B
(zh)
|
2011-07-27 |
2016-08-17 |
阿斯利康(瑞典)有限公司 |
2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用于治疗癌症
|
CN103172641B
(zh)
|
2011-12-20 |
2014-06-11 |
钱卫 |
杂环胺基烷氧基取代的喹唑啉衍生物及其用途
|
AR092031A1
(es)
|
2012-07-26 |
2015-03-18 |
Merck Sharp & Dohme |
Inhibidores del canal de potasio medular externo renal
|
CN102936216B
(zh)
|
2012-12-05 |
2015-03-04 |
南京药石药物研发有限公司 |
7,9-二氧代-2,6-氮杂-螺[3.5]壬-2-甲酸叔丁酯及其中间体的制备方法
|
EP2951185B1
(en)
|
2013-01-29 |
2016-12-21 |
Aptinyx Inc. |
Spiro-lactam nmda receptor modulators and uses thereof
|
EP2951182B1
(en)
|
2013-01-29 |
2020-03-18 |
Aptinyx Inc. |
Spiro-lactam nmda receptor modulators and uses thereof
|
LT2951183T
(lt)
|
2013-01-29 |
2019-05-27 |
Aptinyx Inc. |
Spiro-laktamo nmda receptorių moduliatoriai ir jų panaudojimas
|
PE20151437A1
(es)
|
2013-01-29 |
2015-10-10 |
Naurex Inc |
Moduladores de receptores nmda de espiro-lactama y sus usos
|
US9738650B2
(en)
|
2013-01-29 |
2017-08-22 |
Aptinyx Inc. |
Spiro-lactam NMDA receptor modulators and uses thereof
|
CN103171641B
(zh)
|
2013-03-19 |
2015-07-15 |
浙江大学 |
具备轮动功能的弹跳机器人
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
TWI651310B
(zh)
*
|
2014-02-20 |
2019-02-21 |
日商日本煙草產業股份有限公司 |
三化合物及其醫藥用途
|
GB2528480A
(en)
|
2014-07-23 |
2016-01-27 |
Givaudan Sa |
Improvements in or relating to organic compounds
|
GB201416346D0
(en)
|
2014-09-16 |
2014-10-29 |
Shire Internat Gmbh |
Spirocyclic derivatives
|
WO2017201285A1
(en)
|
2016-05-19 |
2017-11-23 |
Aptinyx Inc. |
Spiro-lactam nmda receptor modulators and uses thereof
|
MX2018014202A
(es)
|
2016-05-19 |
2019-06-20 |
Aptinyx Inc |
Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
|
CA3031537A1
(en)
|
2016-08-01 |
2018-02-08 |
Aptinyx Inc. |
Spiro-lactam nmda receptor modulators and uses thereof
|
KR102462288B1
(ko)
|
2016-08-01 |
2022-11-01 |
앱티닉스 인크. |
스피로-락탐 및 비스-스피로-락탐 nmda 수용체 조정제 및 그의 용도
|
CN109843889B
(zh)
|
2016-08-01 |
2022-03-15 |
阿普廷伊克斯股份有限公司 |
螺-内酰胺nmda调节剂和使用其的方法
|
KR102503590B1
(ko)
|
2016-08-01 |
2023-02-24 |
앱티닉스 인크. |
스피로-락탐 nmda 수용체 조정제 및 그의 용도
|
CA3031539C
(en)
|
2016-08-01 |
2023-11-28 |
Aptinyx Inc. |
Spiro-lactam nmda receptor modulators and uses thereof
|
MX2020008106A
(es)
|
2018-01-31 |
2020-09-25 |
Aptinyx Inc |
Moduladores del receptor nmda espiro-lactama y usos de los mismos.
|
CN112204031A
(zh)
|
2018-01-31 |
2021-01-08 |
阿普廷伊克斯股份有限公司 |
螺-内酰胺nmda受体调节剂及其用途
|
US20210308101A1
(en)
|
2019-11-11 |
2021-10-07 |
Aptinyx Inc. |
Methods of treating fibromyalgia
|
US20210139489A1
(en)
|
2019-11-11 |
2021-05-13 |
Aptinyx Inc. |
Methods of treating painful diabetic peripheral neuropathy
|
AU2020398840A1
(en)
|
2019-12-04 |
2022-05-26 |
Aptinyx Inc. |
Methods of treating cognitive impairment associated with neurodegenerative disease
|